21 avril 2023 – At its meeting on 26 April 2023, the Federal Council decided to extend the funding programme for Covid-19 drugs until 30 June 2024. This means that the development of the drug from GeNeuro SA against neuropsychiatric symptoms in post-Covid 19 disease and the drug from Noorik Biopharmaceuticals AG for the treatment of hospitalised Covid-19 patients who are at high risk of acute respiratory failure can continue to be supported.

For more information, see here.